Gastritis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Gastritis – Pipeline Review, H1 2018’, provides an overview of the Gastritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


– The report provides a snapshot of the global therapeutic landscape of Gastritis

– The report reviews pipeline therapeutics for Gastritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gastritis therapeutics and enlists all their major and minor projects

– The report assesses Gastritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gastritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gastritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BCWorld Pharm Co Ltd

Daewon Pharm Co Ltd

Daewoong Pharmaceutical Co Ltd

Recce Ltd

RedHill Biopharma Ltd

Sequella Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gastritis Overview 6

Gastritis Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 10

Gastritis Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Gastritis Companies Involved in Therapeutics Development 19

BCWorld Pharm Co Ltd 19

Daewon Pharm Co Ltd 19

Daewoong Pharmaceutical Co Ltd 20

Recce Ltd 20

RedHill Biopharma Ltd 21

Sequella Inc 21

Gastritis Drug Profiles 22

AK-002 Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

BCWPA-001 Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

DW-3101 Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

DWJ-1366 Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

HPi-1 Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

netazepide Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ondansetron hydrochloride CR Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

RECCE-327 Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SQ-109 Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Gastritis Dormant Projects 46

Gastritis Product Development Milestones 47

Featured News & Press Releases 47

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 47

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 47

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 48

Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 49

Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 50

Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for Gastritis, H1 2018 7

Number of Products under Development by Companies, H1 2018 9

Products under Development by Companies, H1 2018 10

Number of Products by Stage and Target, H1 2018 12

Number of Products by Stage and Mechanism of Action, H1 2018 14

Number of Products by Stage and Route of Administration, H1 2018 16

Number of Products by Stage and Molecule Type, H1 2018 18

Gastritis Pipeline by BCWorld Pharm Co Ltd, H1 2018 19

Gastritis Pipeline by Daewon Pharm Co Ltd, H1 2018 20

Gastritis Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018 20

Gastritis Pipeline by Recce Ltd, H1 2018 20

Gastritis Pipeline by RedHill Biopharma Ltd, H1 2018 21

Gastritis Pipeline by Sequella Inc, H1 2018 21

Gastritis Dormant Projects, H1 2018 46

List of Figures

List of Figures

Number of Products under Development for Gastritis, H1 2018 7

Number of Products under Development by Companies, H1 2018 8

Number of Products by Targets, H1 2018 11

Number of Products by Stage and Targets, H1 2018 11

Number of Products by Mechanism of Actions, H1 2018 13

Number of Products by Stage and Mechanism of Actions, H1 2018 13

Number of Products by Routes of Administration, H1 2018 15

Number of Products by Stage and Routes of Administration, H1 2018 15

Number of Products by Molecule Types, H1 2018 17

Number of Products by Stage and Molecule Types, H1 2018 17


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports